178 related articles for article (PubMed ID: 9134501)
1. Sequences in the ligand-binding domains of the human androgen and progesterone receptors which determine their distinct ligand identities.
Vivat V; Gofflo D; Garcia T; Wurtz JM; Bourguet W; Philibert D; Gronemeyer H
J Mol Endocrinol; 1997 Apr; 18(2):147-60. PubMed ID: 9134501
[TBL] [Abstract][Full Text] [Related]
2. Functional in vivo interaction between the amino-terminal, transactivation domain and the ligand binding domain of the androgen receptor.
Doesburg P; Kuil CW; Berrevoets CA; Steketee K; Faber PW; Mulder E; Brinkmann AO; Trapman J
Biochemistry; 1997 Feb; 36(5):1052-64. PubMed ID: 9033395
[TBL] [Abstract][Full Text] [Related]
3. Domain interactions between coregulator ARA(70) and the androgen receptor (AR).
Zhou ZX; He B; Hall SH; Wilson EM; French FS
Mol Endocrinol; 2002 Feb; 16(2):287-300. PubMed ID: 11818501
[TBL] [Abstract][Full Text] [Related]
4. Ligand-dependent cross-talk between steroid and thyroid hormone receptors. Evidence for common transcriptional coactivator(s).
Zhang X; Jeyakumar M; Bagchi MK
J Biol Chem; 1996 Jun; 271(25):14825-33. PubMed ID: 8662980
[TBL] [Abstract][Full Text] [Related]
5. Specific recognition of androgens by their nuclear receptor. A structure-function study.
Poujol N; Wurtz JM; Tahiri B; Lumbroso S; Nicolas JC; Moras D; Sultan C
J Biol Chem; 2000 Aug; 275(31):24022-31. PubMed ID: 10787411
[TBL] [Abstract][Full Text] [Related]
6. Human androgen receptor mutation disrupts ternary interactions between ligand, receptor domains, and the coactivator TIF2 (transcription intermediary factor 2).
Lim J; Ghadessy FJ; Abdullah AA; Pinsky L; Trifiro M; Yong EL
Mol Endocrinol; 2000 Aug; 14(8):1187-97. PubMed ID: 10935543
[TBL] [Abstract][Full Text] [Related]
7. Ligand- and coactivator-mediated transactivation function (AF2) of the androgen receptor ligand-binding domain is inhibited by the cognate hinge region.
Wang Q; Lu J; Yong EL
J Biol Chem; 2001 Mar; 276(10):7493-9. PubMed ID: 11102454
[TBL] [Abstract][Full Text] [Related]
8. Mutant and wild-type androgen receptors exhibit cross-talk on androgen-, glucocorticoid-, and progesterone-mediated transcription.
Yen PM; Liu Y; Palvimo JJ; Trifiro M; Whang J; Pinsky L; Jänne OA; Chin WW
Mol Endocrinol; 1997 Feb; 11(2):162-71. PubMed ID: 9013763
[TBL] [Abstract][Full Text] [Related]
9. Towards the mapping of the progesterone and androgen receptors.
Ojasoo T; Delettré J; Mornon JP; Turpin-VanDycke C; Raynaud JP
J Steroid Biochem; 1987; 27(1-3):255-69. PubMed ID: 3695484
[TBL] [Abstract][Full Text] [Related]
10. Induction of cre recombinase activity using modified androgen receptor ligand binding domains: a sensitive assay for ligand-receptor interactions.
Kaczmarczyk SJ; Green JE
Nucleic Acids Res; 2003 Aug; 31(15):e86. PubMed ID: 12888538
[TBL] [Abstract][Full Text] [Related]
11. Residues in the ligand binding domain that confer progestin or glucocorticoid specificity and modulate the receptor transactivation capacity.
Robin-Jagerschmidt C; Wurtz JM; Guillot B; Gofflo D; Benhamou B; Vergezac A; Ossart C; Moras D; Philibert D
Mol Endocrinol; 2000 Jul; 14(7):1028-37. PubMed ID: 10894152
[TBL] [Abstract][Full Text] [Related]
12. The novel progestin drospirenone and its natural counterpart progesterone: biochemical profile and antiandrogenic potential.
Fuhrmann U; Krattenmacher R; Slater EP; Fritzemeier KH
Contraception; 1996 Oct; 54(4):243-51. PubMed ID: 8922878
[TBL] [Abstract][Full Text] [Related]
13. Partial androgen insensitivity and correlations with the predicted three dimensional structure of the androgen receptor ligand-binding domain.
Yong EL; Tut TG; Ghadessy FJ; Prins G; Ratnam SS
Mol Cell Endocrinol; 1998 Feb; 137(1):41-50. PubMed ID: 9607727
[TBL] [Abstract][Full Text] [Related]
14. Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone.
Sack JS; Kish KF; Wang C; Attar RM; Kiefer SE; An Y; Wu GY; Scheffler JE; Salvati ME; Krystek SR; Weinmann R; Einspahr HM
Proc Natl Acad Sci U S A; 2001 Apr; 98(9):4904-9. PubMed ID: 11320241
[TBL] [Abstract][Full Text] [Related]
15. Crystal structure of the T877A human androgen receptor ligand-binding domain complexed to cyproterone acetate provides insight for ligand-induced conformational changes and structure-based drug design.
Bohl CE; Wu Z; Miller DD; Bell CE; Dalton JT
J Biol Chem; 2007 May; 282(18):13648-55. PubMed ID: 17311914
[TBL] [Abstract][Full Text] [Related]
16. Mutational analysis of the androgen receptor AF-2 (activation function 2) core domain reveals functional and mechanistic differences of conserved residues compared with other nuclear receptors.
Slagsvold T; Kraus I; Bentzen T; Palvimo J; Saatcioglu F
Mol Endocrinol; 2000 Oct; 14(10):1603-17. PubMed ID: 11043576
[TBL] [Abstract][Full Text] [Related]
17. Disrupted amino- and carboxyl-terminal interactions of the androgen receptor are linked to androgen insensitivity.
Thompson J; Saatcioglu F; Jänne OA; Palvimo JJ
Mol Endocrinol; 2001 Jun; 15(6):923-35. PubMed ID: 11376111
[TBL] [Abstract][Full Text] [Related]
18. Characterization of two cis-acting DNA elements involved in the androgen regulation of the probasin gene.
Rennie PS; Bruchovsky N; Leco KJ; Sheppard PC; McQueen SA; Cheng H; Snoek R; Hamel A; Bock ME; MacDonald BS
Mol Endocrinol; 1993 Jan; 7(1):23-36. PubMed ID: 8446105
[TBL] [Abstract][Full Text] [Related]
19. Impaired helix 12 dynamics due to proline 892 substitutions in the androgen receptor are associated with complete androgen insensitivity.
Elhaji YA; Stoica I; Dennis S; Purisima EO; Lumbroso R; Beitel LK; Trifiro MA
Hum Mol Genet; 2006 Mar; 15(6):921-31. PubMed ID: 16449235
[TBL] [Abstract][Full Text] [Related]
20. Human androgen receptor gene ligand-binding-domain mutations leading to disrupted interaction between the N- and C-terminal domains.
Jääskeläinen J; Deeb A; Schwabe JW; Mongan NP; Martin H; Hughes IA
J Mol Endocrinol; 2006 Apr; 36(2):361-8. PubMed ID: 16595706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
